iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Strides Pharma Gains 2% as USFDA Approves Cardiac Drug

25 Sep 2023 , 11:04 AM

Strides Pharma Science shares rose by 2% in early trade on September 25 due to its subsidiary obtaining USFDA approval for a cardiac drug. The stock was priced at Rs 509.95, up by Rs 11.30 (2.27%) on the BSE during early trade.

Strides Pharma Global Pte Limited, a subsidiary, received USFDA approval for Icosapent Ethyl Capsules (0.5 gram and 1 gram), a medication used in conjunction with other drugs to reduce cardiovascular risks. The product is bioequivalent and therapeutically equivalent to Vascepa (Reference Listed Drug) and will be produced in Bengaluru.

Strides Pharma has a significant number of approved ANDAs (Abbreviated New Drug Applications) with the USFDA and plans to launch around 60 new products in the US within three years. Earlier in the month, the subsidiary received tentative approval for its New Drug Application (NDA) and Dolutegravir tablets from the USFDA, both to be manufactured in Bengaluru.

For feedback and suggestions, write to us at editorial@iifl.com

 

Related Tags

  • news
  • Pharma
  • stocks
  • Strides Pharma
  • Top News
  • USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

SBI Card Q4 Profit Slips 20%
25 Apr 2025|11:17 PM
HUL Q4 Net Profit Rises to ₹2,493 Crore
25 Apr 2025|10:59 PM
Sensex and Nifty in Red on April 25, 2025
25 Apr 2025|02:08 PM
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.